Comparative Pharmacology
Head-to-head clinical analysis: SELARSDI versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELARSDI versus TZ 3.
SELARSDI vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective angiotensin II type 1 receptor antagonist that blocks vasoconstriction and aldosterone secretion.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
Intravenous 0.15 mg/kg every 8 hours for 14 days.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 11 hours (range 7–15 hours), supporting twice-daily dosing; half-life may be prolonged in renal impairment.
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Primarily renal excretion of unchanged drug (approximately 70%) and glucuronide conjugate (approximately 20%); biliary/fecal elimination accounts for less than 10%.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown